Novo Nordisk A/S (NONOF)
| Market Cap | 241.55B |
| Revenue (ttm) | 49.58B |
| Net Income (ttm) | 16.30B |
| Shares Out | n/a |
| EPS (ttm) | 3.67 |
| PE Ratio | 14.82 |
| Forward PE | 14.61 |
| Dividend | 1.66 (2.98%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 4,153 |
| Average Volume | 98,678 |
| Open | 57.50 |
| Previous Close | 55.77 |
| Day's Range | 56.34 - 58.00 |
| 52-Week Range | 42.01 - 94.05 |
| Beta | 0.35 |
| RSI | 68.75 |
| Earnings Date | Feb 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
European Stocks Rise as Novo Nordisk (NVO) Boosts Healthcare Sector
European Stocks Rise as Novo Nordisk (NVO) Boosts Healthcare Sector
Novo Nordisk (NVO) Rises on U.S. Launch of Oral Wegovy
Novo Nordisk (NVO) Rises on U.S. Launch of Oral Wegovy
Novo Nordisk: Wegovy Pill Is Not A Game Changer
Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline is weak. See why NVO stock is a Hold now.
Novo Nordisk Launches First GLP-1 Weight Loss Pill in the U.S.
Novo Nordisk Launches First GLP-1 Weight Loss Pill in the U.S.
Novo Nordisk: NVO Stock To $100?
Novo Nordisk's (NYSE: NVO) Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x story moving forward, provided it effectively...
Chevron, Nvidia, Novo Nordisk, Zeta Global And Exxon Mobil: Why These 5 Stocks Are On Investors' Radars Today
Major U.S. stock indexes closed higher Monday, with the Dow Jones Industrial Average climbing 1.2% to 48,977.18. The S&P 500 added 0.6% to 6,902.05, while the Nasdaq advanced 0.69% to 23,395.82. Over ...
Final Trade: NVO, JPM, COST, MPC
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Novo Nordisk (NVO) Announces Leadership Change Amid Restructuring
Novo Nordisk (NVO) Announces Leadership Change Amid Restructuring
Eli Lilly Lags In The Weight Loss Pill War. But It Has A Plan.
Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight loss drugs. But Lilly has a rival drug in the pipeline.
Novo Nordisk memo shows departure of U.S. public affairs head: Reuters
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
Novo Nordisk A/S (NYSE: NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025 . Novo Nordisk stock is charging ahead with explosive momentum. What’s fueling NVO mo...
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
Novo Nordisk A/S (NYSE: NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025.
Market Today: Chevron, Novo Nordisk and Versant Headline Moves
Market Today: Chevron, Novo Nordisk and Versant Headline Moves
Novo Nordisk launches Wegovy weight-loss pill in US, triggering price war
First and only GLP-1 pill on the market costs significantly less than injectable versions The first pill version of the blockbuster GLP-1 weight loss drugs has been launched in the US by Novo Nordisk ...
China Market Unsettled, But Novo Nordisk's Oral Wegovy May Keep Revenue On Track
Novo Nordisk A/S launches oral Wegovy in the U.S. with aggressive pricing as China patent expiry looms. Click for this updated look at NVO stock prospects.
First pill version of Wegovy for obesity launches in US
Americans can now purchase a starter dose of Novo Nordisk’s weight loss drug Wegovy in pill form, the company announced Monday, pledging widespread availability. The 1.5 milligram starter dose of a on...
Novo Nordisk’s weight-loss pill is available. Here’s why Lilly’s and Viking’s stocks are down.
Novo Nordisk’s wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
Hims & Hers: A Great Moment To Buy The Dip
Hims & Hers is achieving tremendous revenue growth with a renewed Novo Nordisk weight loss partnership. Click here to read an analysis of HIMS stock now.
Wegovy goes viral: Novo launches US$149 monthly weight-loss tablet
Danish drugmaker Novo Nordisk is launching its once-daily Wegovy pill in the United States on Monday, offering 1.5 milligram (mg) and four mg doses at US$149 per month for self-paying patients in an i...
Novo Nordisk (NVO) Expands Wegovy Availability Across the U.S.
Novo Nordisk (NVO) Expands Wegovy Availability Across the U.S.
Novo Nordisk (NVO) Rises on Wegovy Pill Launch
Novo Nordisk (NVO) Rises on Wegovy Pill Launch
I Expect Novo Nordisk To Outperform Eli Lilly In 2026: Here's Why
Exclusive: Novo Nordisk's US public affairs head leaves company
Danish obesity drugmaker Novo Nordisk's head of public affairs in the U.S. has left the company, according to an internal memo seen by Reuters, at a time when the firm is battling to revive its fortun...
Novo Nordisk Launches Wegovy™ Pill, Expanding Patient Choice and Access With knownwell as a Recognized NovoCare® Provider
BOSTON--(BUSINESS WIRE)--Novo Nordisk today announced the U.S. launch of the Wegovy™ pill, the first oral GLP-1 option approved by the Food and Drug Administration for chronic weight management. The i...
Novo Nordisk Stock Rises as Wegovy Pill Hits the U.S. Market
Novo Nordisk Stock Rises as Wegovy Pill Hits the U.S. Market